Region Stockholm – SLSO
- Address
- lock Available on a paid plan
Neurology and Neurodegenerative Disorders
At Region Stockholm – SLSO the focus is on developing new treatments for diseases of the nervous system, aiming to slow disease progression and improve quality of life for patients.
- Investigating innovative therapies for multiple sclerosis
- Testing disease‑modifying agents in amyotrophic lateral sclerosis
- Evaluating neuroprotective strategies for Parkinson's disease
- Exploring treatments for progressive supranuclear palsy
These studies aim to preserve neurological function, reduce disability, and provide new options for patients facing chronic neurodegenerative conditions.
Autoimmune and Inflammatory Diseases
The centre’s immunology program targets a range of autoimmune disorders, assessing novel biologics and targeted agents to modulate the immune response.
- Assessing efficacy of therapies for Sjogren’s syndrome
- Evaluating treatments for chronic inflammatory demyelinating polyneuropathy
- Studying new options for rheumatoid arthritis
- Testing interventions in polymyalgia rheumatica
The goal is to achieve better disease control, reduce flare‑ups, and improve long‑term outcomes for patients with immune‑mediated conditions.
Metabolism, Diabetes and Cardiovascular Health
Research in metabolic disorders concentrates on improving glycemic control, reducing cardiovascular risk, and supporting weight management.
- Investigating novel agents for type 2 diabetes
- Exploring therapies that protect pancreatic function in type 1 diabetes
- Evaluating treatments to lower triglyceride levels and obesity‑related complications
- Studying drugs that prevent heart‑failure events in patients with cardiovascular disease
These trials seek to enhance metabolic health, limit disease complications, and provide new therapeutic choices for at‑risk populations.
Respiratory and Infectious Diseases
The site conducts studies aimed at improving outcomes for chronic lung conditions and vaccine‑related research.
- Testing new inhaled combinations for chronic obstructive pulmonary disease
- Evaluating therapies for severe asthma
- Assessing vaccine efficacy against influenza in high‑risk groups
- Investigating preventive strategies for respiratory syncytial virus in older adults
The purpose of these studies is to reduce exacerbations, improve lung function, and strengthen protection against viral infections.
Psychiatry, Mood Disorders and Substance Use
Mental health research at the centre focuses on innovative pharmacologic and non‑pharmacologic approaches to treat mood disorders and addiction.
- Evaluating adjunctive agents for treatment‑resistant major depressive disorder
- Testing new medications for manic episodes in bipolar I disorder
- Studying immunomodulatory therapy for schizophrenia spectrum disorder
- Assessing adjunct treatments to improve outcomes in opioid use disorder
These trials aim to alleviate symptoms, prevent relapse, and offer safer, more effective options for individuals living with psychiatric and addictive illnesses.
Oncology and Tumor Immunology
Oncology research at the site explores cutting‑edge cellular therapies and targeted drugs for solid tumors.
- Investigating CAR‑T cell approaches for tumor antigens
- Evaluating novel immunotherapies combined with RNA‑based vaccines
- Studying safety and efficacy of targeted agents in advanced solid cancers
The objective is to enhance anti‑tumor immunity, improve response rates, and expand treatment options for patients with hard‑to‑treat cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 17 therapeutic areas and 15 of 154 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 145 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 22 by active trials.
lock +21 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Region Stockholm – SLSO
lock Showing 1 of 67 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week randomized, double-blind, placebo-controlled, multi-center Phase 2b study with a 52-week blinded extension and an optional open-label extension—assessing the safety and efficacy of frexalimab, a CD40L-antagonist monoclonal antibody, for the preservation of pancreatic β-cell function in adults and adolescents with newly diagnosed type 1 diabetes on insulin therapy | Sanofi-Aventis Recherche & Developpement | Phase II | Not Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 154 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Riliprubart | 3 | Unknown | 2024-07-31 | 2025-06-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.